A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
← catalyst calendarNCT06777316 · readout ≤ 224 d
Sponsored by Cogent Biosciences, Inc. (industry) · COGT — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
110estimated
Sites
13
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-22 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Cholangiocarcinoma
- Other Solid Tumors, Adult
- FGFR2 Gene Fusion/Rearrangement
- FGFR2 Gene Amplification
- FGFR2 Gene Short Variants
- FGFR3 Gene Fusion/Rearrangement
- FGFR3 Gene Amplification
- FGFR3 Gene Short Variants
- FGFR2 Genetic Alterations
- FGFR3 Genetic Alterations
- Advanced Solid Tumors
Intervention
- Drug: CGT4859
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEs
measured Approximately 12 months
Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - Laboratory results
measured Approximately 12 months
Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - ECG results
measured Approximately 12 months
Phase 2: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)
measured Approximately 8 months
Permalink · COGT's whole pipeline · Catalyst calendar · Every registered study · What changed